Cigerim, LeventKaplan, Volkan2025-05-102025-05-1020230886-96342151-090310.1080/08869634.2020.18244112-s2.0-85091078291https://doi.org/10.1080/08869634.2020.1824411https://hdl.handle.net/20.500.14720/7109Cigerim, Levent/0000-0001-5218-8568; Kaplan, Volkan/0000-0002-7605-1125Objective To assess the effects of naproxen sodium-codeine phosphate, naproxen sodium-dexamethasone, and naproxen sodium on myofascial pain. Methods This randomized, double-blind prospective clinical study was conducted with patients who applied with the complaint of pain in the temporomandibular region. A total of 169 patients were randomly divided into four groups and received the following treatments: Group A: naproxen sodium 550 mg; Group B: naproxen sodium 550 mg + codeine phosphate 30 mg; Group C: naproxen sodium 550 mg + single-dose dexamethasone 8 mg, and Group D: paracetamol 500 mg. Results Of the patients, 132 were female, and 37 were male, with a mean age of 27.04 +/- 10.56 (18-69 years). Analgesic efficiency of the naproxen sodium-codeine phosphate group was the most effective at the 2nd week and 4th week (p< 0.05). Conclusion Naproxen sodium-codeine phosphate might be preferred as an analgesic in similar cases with severe myofascial pain.eninfo:eu-repo/semantics/closedAccessTemporomandibular DisordersCodeineNaproxenDexamethasonePainArticle412N/AQ211912532941116WOS:000570273800001